In-Depth Research On:
Xoma Ltd. (XOMA)

Sign Up Now to Download a Free Research Report on XOMA

Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.
Select your areas of interest / would you like to receive the newsletter?




Download Adobe Reader Having problems viewing PDF files? Download Adobe Reader.

Xoma Ltd.

XOMA shares soared 20.16 percent to close at $4.59 a share Tuesday. The stock traded between $4.02 and $4.85 on volume 5.75 million shares traded. MLV & Co. has recently upgraded XOMA’s rating to “buy” from “hold” after the company announced it is “finalizing its plans for a gevokizumab Phase 3 program in pyoderma gangrenosum”.

Going forward .... (see research report)


RESEARCH REPORT ON XOMA
Download Free Report Now


Preview Pages of Actual Research Report

Download Adobe Reader Having problems viewing PDF files? Download Adobe Reader. Research Report on    Research Report on    Research Report on    

Research Report on    Research Report on    Research Report on